Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - 1 Jan 2008

Shoji F, Yano T, Yoshino I, Mori D, Yamasaki F, Kohno H, Maehara Y

Abstract excerpt

AIMS: Gefitinib shows prominent anti-tumor activity against advanced or recurrent non-small cell lung cancer (NSCLC). However, most gefitinib-responsive patients ultimately relapse. We reviewed postoperatively recurrent NSCLC patients who received gefitinib treatment, and analyzed both the clinical features and manifestations of treatment failure in patients who initially responded to gefitinib. METHODS: From...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Lung Neoplasms

Share to Neoplasm Recurrence, Local

Share to Quinazolines

Share to Treatment Failure

Source

Identifiers

PMID: 17449217
DOI: 10.1016/j.ejso.2007.03.005

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.PMID 17449217Read ↗

Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.Semantic proximity Read ↗

Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.Semantic proximity Read ↗

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative RecurrenceSemantic proximity Read ↗

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer.Semantic proximity Read ↗

Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.Semantic proximity Read ↗

The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.Semantic proximity Read ↗

Is radical local therapy effective in postoperative recurrent EGFR-mutated non-small cell lung cancer?Semantic proximity Read ↗

Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.Semantic proximity Read ↗

Examination of the effectiveness of local therapy for oligo-recurrence of EGFR-mutated NSCLC.Semantic proximity Read ↗

Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.